Assessment of platelet response to clopidogrel through measurement of ADP-induced Akt phosphorylation

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 8, 2009, Pages 1411-1413

  Carrie D ^a   Garcia, C ^a   Gratacap, M P ^b   Voisin, S ^a   Payrastre, B ^a,b   Sié, Pierre ^a,b,c  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSERM   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PROTEIN KINASE B; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; AGED; BLOOD PLATELETS; FEMALE; HUMANS; MALE; METHODS; MIDDLE AGED; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TICLOPIDINE;

EID: 67949115699     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03485.x     Document Type: Article

References (10)

1. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97: 282-7.
2. Blindt R, Stellbrink K, de Taeye A, Müller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-34.
3. Bonello F, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-Georges F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-6.
4. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO. J Am Coll Cardiol 2008; 52: 1128-33.
5. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
6. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007; 5 (Suppl. 1): 230-5.
7. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets: definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-52.
8. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279: 4186-95.
9. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119: 277-84.
10. Gratacap MP, Herault JP, Viala C, Ragab J, Savi P, Herbert JM, Chap H, Plantavid M, Payrastre B. FcγRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood 2000; 96: 3439-46.